Pharmacological Inhibition of PD-L1 as an Antagonist of Skin Damage and Cancer in response to Acute and Chronic Solar UV Exposure and Other Environmental Toxicants

Case ID:

This innovation is the development of a pharmacological inhibitor of PD-L1 to prevent or reduce the negative impact of acute and chronic solar UV exposure and environmental toxicants on the skin. PD-L1 is a molecule involved in immune regulation and can be upregulated in response to UV radiation and environmental toxins. However, overexpression of PD-L1 can lead to immune evasion by cancer cells and contribute to skin damage. By blocking PD-L1, the immune system’s response can be enhanced, leading to better recognition and elimination of cancer cells and minimizing skin damage. This approach holds potential for the development of therapies or interventions to protect against skin cancer and mitigate the adverse effects of UV exposure and environmental toxins on the skin.

Current approaches to treat the negative impact of solar UV exposure and environmental toxicants that contribute to skin damage, skin cancer, and premature aging primarily rely on sun protection measures and existing skin cancer treatments, but they have limitations such as incomplete protection and associated side effects. By blocking PD-L1, this innovation aims to improve the recognition and elimination of cancer cells by the immune system, offering a novel and potentially more effective strategy for skin protection and cancer prevention.


  • Skin cancer prevention
  • Skin damage mitigation
  • Anti-aging and photorejuvenation
  • Dermatologic therapeutics


  • Enhanced immune response
  • Minimize skin damage
  • Complimentary to sun protection measures
Patent Information:
Contact For More Information:
Garrett Edmunds
Licensing Manager, UAHS-TLA
The University of Arizona
Lead Inventor(s):
Sally Dickinson
Georg Wondrak
Clara Curiel